Literature DB >> 10800094

DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice.

A Amici1, A Smorlesi, G Noce, G Santoni, P Cappelletti, L Capparuccia, R Coppari, R Lucciarini, C Petrelli, M Provinciali.   

Abstract

Genetic immunization against tumor antigens is an effective way to induce an immune response able to oppose cancer progression. Overexpression of HER-2/neu can lead to neoplastic transformation and has been found in many human primary breast cancers. We constructed DNA expression vectors encoding the full-length neu oncogene of rat cDNA (pCMV-NeuNT), the neu extracellular domain (pCMV-ECD), or the neu extracellular and transmembrane domains (pCMV-ECD-TM). We evaluated whether i.m. injection of these plasmids induces protection against the development of mammary tumors occurring spontaneously in FVB/N neu-transgenic mice. We found that pCMV-ECD-TM induced the best protection, whereas both pCMV-ECD and pCMV-NeuNT were less effective. The coinjection with a bicistronic vector for murine IL-12 increased the efficacy of pCMV-ECD and pCMV-NeuNT plasmids, and led to the same protection obtained with pCMV-ECD-TM alone. Anti-neuECD antibodies were detected in pCMV-ECD-TM vaccinated mice and, after coinjection with pCMV-IL12 plasmids, they appeared also in animals immunized with pCMV-ECD. Our data demonstrate the effectiveness of DNA vaccination using truncated Neu plasmids in inducing antitumor protection in a spontaneous mammary tumor model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10800094     DOI: 10.1038/sj.gt.3301151

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.

Authors:  Rachael B Rowswell-Turner; Jamie L Harden; Raji E Nair; Tao Gu; Mehmet O Kilinc; Nejat K Egilmez
Journal:  J Immunol       Date:  2011-09-09       Impact factor: 5.422

2.  Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.

Authors:  Fateme Sadri-Ardalani; Mahdi Shabani; Mohammad Mehdi Amiri; Motahareh Bahadori; Shaghayegh Emami; Ali Reza Sarrafzadeh; Farzaneh Noutash-Haghighat; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Tumour Biol       Date:  2015-08-19

3.  DNA vaccination against oncoantigens: A promise.

Authors:  Manuela Iezzi; Elena Quaglino; Augusto Amici; Pier-Luigi Lollini; Guido Forni; Federica Cavallo
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

4.  Alphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.

Authors:  Xiaoyan Wang; Jian-Ping Wang; Maureen F Maughan; Lawrence B Lachman
Journal:  Breast Cancer Res       Date:  2004-11-29       Impact factor: 6.466

5.  "Omics" and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas.

Authors:  Elda Tagliabue; Manuela Campiglio
Journal:  Front Oncol       Date:  2014-11-18       Impact factor: 6.244

6.  Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.

Authors:  Mauro Provinciali; Alessandra Barucca; Fiorenza Orlando; Elisa Pierpaoli
Journal:  Sci Rep       Date:  2017-06-08       Impact factor: 4.379

7.  Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD).

Authors:  Federico Gabrielli; Roberto Salvi; Chiara Garulli; Cristina Kalogris; Serena Arima; Luca Tardella; Paolo Monaci; Serenella M Pupa; Elda Tagliabue; Maura Montani; Elena Quaglino; Lorenzo Stramucci; Claudia Curcio; Cristina Marchini; Augusto Amici
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

8.  Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers.

Authors:  Cristina Marchini; Cristina Kalogris; Chiara Garulli; Lucia Pietrella; Federico Gabrielli; Claudia Curcio; Elena Quaglino; Federica Cavallo; Augusto Amici
Journal:  Front Oncol       Date:  2013-05-14       Impact factor: 6.244

9.  Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.

Authors:  Yesim Eralp; Xiaoyan Wang; Jian-Ping Wang; Maureen F Maughan; John M Polo; Lawrence B Lachman
Journal:  Breast Cancer Res       Date:  2004-04-07       Impact factor: 6.466

10.  Evaluation of Different DNA Vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS) in Pigs.

Authors:  Stefano Petrini; Giorgio Ramadori; Riccardo Villa; Paolo Borghetti; Elena de Angelis; Anna Maria Cantoni; Attilio Corradi; Augusto Amici; Maura Ferrari
Journal:  Vaccines (Basel)       Date:  2013-10-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.